AI for drug safety, medical information, and regulatory migration

Pharma-grade AI workflows for the work trapped in inboxes, PDFs, and legacy dossiers.

RegulaVita helps life sciences teams transform unstructured medical information requests, pharmacovigilance inbox traffic, SmPCs, and Module 3 CTD documents into structured, reviewable, audit-ready outputs.

Live workflow console

PV Inbox Responses

Source packet
Illustrated pharmaceutical blueprint document
1Triage

Classifies inquiry type, product, country, and triggers.

2Research

Searches approved source libraries and literature.

3Draft

Creates a structured response with traceable evidence.

4Review

Routes output to human-in-the-loop decision points.

ICH E2B(R3) structured case thinkingFDA 21 CFR Part 11 audit trail postureEMA IDMP and SPOR data orientationGxP and GAMP 5 validation readinessHuman-in-the-loop review thresholdsPrivate cloud or on-prem deployment where requiredICH E2B(R3) structured case thinkingFDA 21 CFR Part 11 audit trail postureEMA IDMP and SPOR data orientationGxP and GAMP 5 validation readinessHuman-in-the-loop review thresholdsPrivate cloud or on-prem deployment where required

Grounded in real regulated workflows

Built around the shape of actual pharma work, not a generic chatbot wrapper.

The product language from the original site is still here: PV inbox intake, researched responses, IDMP extraction, RIM migration, secure deployment, and validation readiness. The redesign makes those claims specific and inspectable.

433
MI inquiry records processed in a live workflow

429 emails containing 433 individual records since go-live.

76-90
emails per month during embedded use

Sustained daily adoption across the operating team.

711
SmPC PDFs converted for structured RIM import

Qualitative, quantitative, packaging, and language fields.

1,696
Module 3 CTD documents extracted

P.1, P.3.1, P.7, and S.2.1/R.3 workstreams.

Modular platform

Switch on the workflows you actually need.

The safest commercial framing is modular: case intake and response generation are related, but they solve different operational problems and can be priced, validated, and governed separately.

Drug safety operations

PV Inbox Case Intake

Digitalise incoming cases from inboxes and unstructured attachments into predefined data categories for downstream review.

AI reads email bodies, PDFs, Word files, logs, images, and other supporting material, then maps the content into pharmaceutical-specific schemas with coding, redaction, classification, and human-in-the-loop review as defined by corporate guidance.

Evidence

The live MI workflow has handled hundreds of inquiries while preserving structured fields for later audit and trend analysis.

Structured outputs
Reviewer checkpoints
Source traceability

Interactive workflow

From manual inbox drag to governed AI throughput.

Toggle between the legacy operating pattern and the RegulaVita augmented version. The goal is not replacing medical judgement; it is removing the repetitive conversion, search, formatting, and routing work around it.

RegulaVita AI workflow
Minutes
Secure intake

Email, PDF, Word, image, logs

Structured extraction

Pydantic-style schemas and vocabularies

Source research

SmPCs, PubMed, EMBASE, Cochrane, internal data

Human review

Risk-based checkpoints and reviewer edits

Audit pack

Decision trail, references, and structured output

Portfolio signals

Country-product hotspots and unmet need trends

<5 min
typical processing target
90%+
cost reduction model
Audit-ready
structured review trail

Savings model

Explore the economics using the original operating assumptions.

The prior model used 8.3 hours and about $33 per manually processed request, compared with under 5 minutes and under $3 for AI-assisted processing. Adjust monthly volume to see the order of magnitude.

1001,000 requests5,000
Monthly cost avoided
$30,000
Annual cost avoided
$360,000
Manual monthly cost
$33,000
Expert hours returned
8,217

Trust architecture

Regulated AI needs visible control, not magic.

The system is presented as validation-ready, configurable, and reviewable. That is the more credible posture for GxP environments than pretending the model itself is the compliance programme.

Schema first

Structured output models are defined before automation, so the system produces auditable records instead of loose AI prose.

Human governed

Critical decision points stay with trained reviewers, with AI actions captured in traceable review files.

Source controlled

Literature and response generation can be restricted to approved medical databases, SmPCs, and internal source libraries.

Deployable by sensitivity

Cloud API, private Azure, and on-prem options match the sensitivity of public SmPCs, confidential quality data, or patient-linked material.

Deployment tiers
Cloud API

Fastest start for low-sensitivity public documents.

Private Azure

Useful where confidential product data must stay in a controlled tenant.

On-prem

Reserved for high-sensitivity environments with strict network boundaries.

Implementation path
  1. 1Scope the workflow, source systems, SOPs, and review thresholds.
  2. 2Define schemas, controlled vocabularies, and expected output formats.
  3. 3Run a bounded sample against real documents and human-reviewed gold data.
  4. 4Deploy the MVP through secure email forwarding, API integration, or private cloud.
  5. 5Measure throughput, cost, reviewer edits, and signal value before expanding modules.

Research anchors

Framed around the standards and platforms buyers already know.

Validation-ready demo

Show potential customers a system that feels as serious as the problem it solves.

Discuss PV inbox automation, medical information response generation, IDMP extraction, or a scoped compliance workshop around your existing documents and SOPs.

joshua@regulavita.comConnect on LinkedIn
Phone: +27 65 528 4532RegulaVita by Isometry